miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare

View original at finance.yahoo.com
United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare Company Logo The United States AI in Healthcare Market is projected to soar from US$ 10.26 billion in 2025 to US$ 99.77 bil…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The United States AI in Healthcare Market is expected to reach US$ 99.77 billion by 2033 from US$ 10.26 billion in 2025, with a CAGR of 32.88% from 2025 to 2033.

    80% confidence

  • California, Texas, New York, and Florida lead in AI healthcare adoption, bolstering U.S. AI healthcare innovation.

    80% confidence

  • One of the major challenges in the U.S. AI in Healthcare market is ensuring data privacy and compliance with complex regulations such as HIPAA and emerging state-specific laws.

    80% confidence

  • The FDA's support for AI-based medical devices and government programs encouraging healthcare digitization further accelerate industry growth.

    80% confidence

  • Rapid digital transformation, growing demand for precision medicine, robust government support, and the need for affordable healthcare solutions are the main factors propelling the U.S. AI in healthcare market.

    80% confidence

  • Many small and mid-sized hospitals struggle to afford AI technologies, leading to uneven adoption across regions.

    80% confidence

  • The United States is becoming a global leader in healthcare innovation as a result of the acceleration of AI integration brought about by rising healthcare costs and the expansion of big data availability.

    80% confidence

  • AI-powered precision medicine platforms are being deployed across oncology, neurology, and cardiology to identify molecular markers and optimize care delivery.

    80% confidence

  • NLP advancements are accelerating AI adoption across the U.S. healthcare sector by transforming how unstructured clinical data is utilized.

    80% confidence

  • The high cost of implementing AI technologies and the shortage of skilled professionals pose significant barriers to market growth.

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare — Source | Via News | es.VIA.NEWS